Rizatriptan indications and usage: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Rizatriptan}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Indications and Usage== | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN BENZOATE) TABLET, ORALLY DISINTEGRATING [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d93286f5-99f7-4dc5-aa9d-ad73ab8490db | publisher = | date = | accessdate = }}</ref> | MAXALT® and MAXALT-MLT® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. | ||
====Limitations of Use==== | |||
MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks. | |||
MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. | |||
MAXALT is not indicated for the prevention of migraine attacks. | |||
Safety and effectiveness of MAXALT have not been established for cluster headache.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN BENZOATE) TABLET, ORALLY DISINTEGRATING [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d93286f5-99f7-4dc5-aa9d-ad73ab8490db | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 07:09, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
MAXALT® and MAXALT-MLT® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.
Limitations of Use
MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks.
MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)].
MAXALT is not indicated for the prevention of migraine attacks.
Safety and effectiveness of MAXALT have not been established for cluster headache.[1]
References
Adapted from the FDA Package Insert.